Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM